Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

SML3203

Sigma-Aldrich

Tebipenem

≥98% (HPLC)

Synonym(e):

(1R,5S,6S)-2-[1-(1,3-Thiazolin-2-yl)azetidin-3-yl]thio-6-[(R)-1-hydroxyeth yl]-1-methyl-carbapen-2-em-3-carboxylic acid, (4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, L-084 active drug, LJC 11,036, LJC 11036, ME1211 active drug, SPR 859, SPR 994 active drug, SPR-859, SPR-994 active drug, SPR859, SPR994 active drug, TBM, TBM-PI active drug, Tebi-pivoxil active drug, [4R-[4α,5β,6β(R*)]]-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C16H21N3O4S2
CAS-Nummer:
161715-21-5
Molekulargewicht:
383.49
MDL-Nummer:
MFCD00936545
UNSPSC-Code:
51111800
NACRES:
NA.77
Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Farbe

white to beige

Löslichkeit

DMSO: 2 mg/mL, clear

Lagertemp.

−20°C

SMILES String

S1CCN=C1N2CC(C2)SC3=C(N4[C@H]([C@H]3C)[C@H](C4=O)[C@H](O)C)C(=O)O

InChI

1S/C16H21N3O4S2/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)25-9-5-18(6-9)16-17-3-4-24-16/h7-11,20H,3-6H2,1-2H3,(H,22,23)/t7-,8-,10-,11-/m1/s1

InChIKey

GXXLUDOKHXEFBQ-YJFSRANCSA-N

Biochem./physiol. Wirkung

Carbapenem class broad-spectrum β-lactam antibiotic, active metabolite of Tebipenem pivoxil (L-084I; SPR994; Tebi-pivoxil; TBM-P).
Tebipenem (LJC 11,036; SPR859; TBM) is a carbapenem class broad-spectrum β-lactam antibiotic against both gram-positive and gram-negative bacteria, including penicillin-resistant S. pneumoniae (PRSP) and many β-lactamase-producing strains (respective MIC ≤6-200 and ≤25-390 ng/mL), while being less effective against methicillin-resistant S. aureus (MRSA), S. marcescens, and P. aeruginosa (respective MIC ranges 0.2 to12.5, 0.05 to100, 3.13 to >100 μg/mL). TBM is 2- to 64-fold more potent than imipenem, cefdinir, and faropenem against clinical isolates from respiratory and urinary-tract infections.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000187272
0000180386
0000187272
0000187271
0000180386

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Aileen Rubio et al.
ACS infectious diseases, 4(10), 1436-1438 (2018-08-18)
Carbapenems are potent antibacterials with broad-spectrum activity. However, poor oral absorption generally confines this important drug class to in-hospital use by intravenous (IV) administration. The continued rise in drug resistant pathogens creates a need for alternative oral therapies with broad-spectrum
Visanu Thamlikitkul et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 97(12), 1259-1268 (2015-03-15)
To determine in vitro and in vivo activity of tebipenem against ESBL-producing E. coli. Minimum inhibitory concentration (MIC) of tebipenem against 100 clinical isolates of ESBL-producing E. coli was performed by broth micro-dilution technique. Blood and urine samples from 10
Mario A Bianchet et al.
BMC biochemistry, 18(1), 8-8 (2017-05-27)
The carbapenem subclass of β-lactams is among the most potent antibiotics available today. Emerging evidence shows that, unlike other subclasses of β-lactams, carbapenems bind to and inhibit non-classical transpeptidases (L,D-transpeptidases) that generate 3 → 3 linkages in bacterial peptidoglycan. The
Koichi Fujimoto et al.
Antimicrobial agents and chemotherapy, 57(2), 697-707 (2012-11-14)
SM-295291 and SM-369926 are new parenteral 2-aryl carbapenems with strong activity against major causative pathogens of community-acquired infections such as methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Streptococcus pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Moraxella catarrhalis, Haemophilus influenzae (including β-lactamase-negative
S Miyazaki et al.
Antimicrobial agents and chemotherapy, 45(1), 203-207 (2000-12-20)
L-084 (a prodrug of LJC 11,036 [L-036]) is a new oral carbapenem. Here we compared the in vitro and in vivo antibacterial activities of L-036 with those of imipenem, faropenem, ceditoren-pivoxil, cefdinir, amoxicillin, and levofloxacin. The MICs at which 90%
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.